Your browser doesn't support javascript.
loading
Protocol for a phase IV double-blind randomised controlled trial to investigate the effect of the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine on pneumococcal colonisation using the experimental human pneumococcal challenge model in healthy adults (PREVENTING PNEUMO 2).
Liatsikos, Konstantinos; Hyder-Wright, Angela; Pojar, Sherin; Chen, Tao; Wang, Duolao; Davies, Kelly; Myerscough, Christopher; Reine, Jesus; Robinson, Ryan E; Urban, Britta; Mitsi, Elena; Solorzano, Carla; Gordon, Stephen B; Quinn, Angela; Pan, Kaijie; Anderson, Annaliesa S; Theilacker, Christian; Begier, Elizabeth; Gessner, Bradford D; Collins, Andrea; Ferreira, Daniela M.
Afiliação
  • Liatsikos K; Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK.
  • Hyder-Wright A; Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK.
  • Pojar S; Respiratory Research Group, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK.
  • Chen T; Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK.
  • Wang D; Global Health Trials Unit, Liverpool School of Tropical Medicine, Liverpool, UK.
  • Davies K; Global Health Trials Unit, Liverpool School of Tropical Medicine, Liverpool, UK.
  • Myerscough C; Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK.
  • Reine J; Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK.
  • Robinson RE; Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK.
  • Urban B; Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK.
  • Mitsi E; Respiratory Research Group, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK.
  • Solorzano C; Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK.
  • Gordon SB; Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK.
  • Quinn A; Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK.
  • Pan K; Malawi Liverpool Wellcome Trust Clinical Research Programme, Liverpool School of Tropical Medicine, Blantyre, Malawi.
  • Anderson AS; Pfizer Vaccines, Pfizer Inc, Collegeville, Pennsylvania, USA.
  • Theilacker C; Pfizer Vaccines, Pfizer Inc, Collegeville, Pennsylvania, USA.
  • Begier E; Vaccines Research and Development, Pfizer Inc, Pearl River, New York, USA.
  • Gessner BD; Pfizer Vaccines, Pfizer Inc, Collegeville, Pennsylvania, USA.
  • Collins A; Pfizer Vaccines, Pfizer Inc, Collegeville, Pennsylvania, USA.
  • Ferreira DM; Pfizer Vaccines, Pfizer Inc, Collegeville, Pennsylvania, USA.
BMJ Open ; 12(7): e062109, 2022 07 07.
Article em En | MEDLINE | ID: mdl-35798520
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Otite Média / Infecções Pneumocócicas Idioma: En Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Reino Unido
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Otite Média / Infecções Pneumocócicas Idioma: En Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Reino Unido